Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation.

Sci Rep · 2019 · PMC6491445 · PMID 31040359

Europe PMC DOI

hedged sentence

0.0490

closest p · 1.0× alpha

0.0490

boldest claim

The sentences

of borderline significancep = 0.049actually significant

Edoxaban showed better composite outcome than rivaroxaban in patients with body weight >60 kg, of borderline significance (HR 0.672, 95% CI 0.434–0.998, p = 0.049, p for interaction = 0.058).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.